Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

Chiasma, Inc.155 enrolled

Overview

MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.

The study consisted of 2 periods, a Core Treatment Period of up to 7 months and an optional Extension Treatment Period of up to 6 months, for a total study duration of up to 13 months. The Core Treatment Period consisted of 2 phases, a Dose Escalation Phase of at least 2 months to identify the therapeutic dose for each study participant and a Fixed Dose Phase of 2 to 5 months during which the therapeutic dose was maintained. Participants were eligible to enter the Fixed Dose Phase of the Core Treatment Period if they were clinically and biochemically controlled. The same criteria were used to allow entry into the voluntary 6-month Extension Treatment Period. The Core Treatment Period of the study was completed if the participant had at least 2 months of treatment in the Fixed Dose Phase and a total treatment duration of at least 7 months. Participants who elected to continue into the Extension Treatment Period maintained their therapeutic dose during this period. At the end of the study (after the last dose of MYCAPSSA in either the Core Treatment Period or the Extension Treatment Period), there was a 2-week follow-up period for safety assessments.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

155

Conditions

Acromegaly

Interventions

Octreotide capsulesDRUG

Octreotide was provided in hard gelatin capsules.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult subjects, aged 18 to 75 years old, inclusive. * Subjects with acromegaly defined as documented evidence of growth hormone-secreting pituitary tumor that is abnormally responsive to glucose, or documented elevated insulin-like growth factor-1 (IGF-1), who are currently receiving a stable dose of a somatostatin analog for at least the previous 3 months. * A serum IGF-1 level \< 1.3 x the upper limit of normal (ULN) and a serum growth hormone (GH) level \< 2.5 ng/mL. * Subjects able and willing to comply with the requirements of the protocol. * Subjects able to swallow capsules. * Subjects able to understand and sign written informed consent to participate in the study. Exclusion Criteria: * Receiving regular injections of a somatostatin analog less frequently than once a month, ie, longer than every 4 weeks. * Symptomatic cholelithiasis. * Received pituitary radiotherapy within ten years prior to screening. * Undergone pituitary surgery within the prior 6 months. * Any condition that may jeopardize study participation. * Clinically significant gastrointestinal (GI), renal, or hepatic disease as determined by the Investigator. * Conditions (eg, bariatric surgery) significantly affecting gastric acidity or emptying. * Current use (within 1 month) of proton pump inhibitors (PPIs) and current chronic use of H2-antagonists. * Female patients who are pregnant or lactating. * Current or recent (\< 3 months) therapy with pegvisomant. * Current or recent (\< 2 months) therapy with cabergoline.

Locations (36)

Outcomes

Primary Outcomes

Percentage of Responders at the End of the Core Treatment Period

A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Time frame: End of the core treatment period (up to 7 months)

Percentage of Responders at the End of the Extension Treatment Period

Time frame: End of the extension treatment period (up to 13 months)

Secondary Outcomes

Percentage of Participants With Specified IGF-1 and GH Concentrations at Baseline and at the End of the Core Treatment Period

Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at Baseline and at the end of the core treatment period (ECTP): IGF-1 \< 1.3 times the upper limit of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Cedars-Sinai Medical Center

Los Angeles, California, United States

Campus Charité Mitte

Berlin, Germany

ENDOC Center for Endocrine Tumors

Hamburg, Germany

Medizinische Klinik Innenstadt

Munich, Germany

Max Planck Institute of Psychiatry

Munich, Germany

Praxis for Endocrimology and Diabetology in Oldenburg

Oldenburg, Germany

Military Hospital, State Health Center 2nd Department of Internal Medicine

Budapest, Hungary

Semmelweiss University

Budapest, Hungary

University of Pecs

Pécs, Hungary

University of Szeged

Szeged, Hungary

...and 26 more locations

Time frame: Baseline and the end of the core treatment period (up to 7 months)

Maintenance of Response During the Fixed Dose Phase of the Core Treatment Period

Maintenance of response during the fixed dose phase of the core treatment period was defined as the percentage of participants with an insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal at the beginning of the fixed dose phase of the core treatment period and at the end of the core treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.

Time frame: Beginning of the fixed dose phase of the core treatment period and the end of the core treatment period (up to 7 months)

Percentage of Participants With Specified IGF-1 and GH Concentrations at the Beginning and at the End of the Extension Treatment Period

Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at the beginning (BETP) and at the end (EETP) of the extension treatment period: IGF-1 \< 1.3 times the upper level of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Time frame: Beginning and the end of the extension treatment period (up to 6 months)

Maintenance of Response During the Extension Treatment Period

Maintenance of an insulin-like growth factor-1 (IGF-1) response during the extension treatment period was defined as the percentage of participants with an IGF-1 concentration \< 1.3 times the upper limit of normal at the beginning of the extension treatment period and at the end of the extension treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.

Time frame: Beginning of the extension treatment period and the end of the extension treatment period (up to 13 months)

Percentage of Participants With Improved or Maintained Acromegaly Symptoms at the End of the Extension Treatment Period

The severity (absent, mild, moderate, severe) of the 5 acromegaly symptoms headache, perspiration, asthenia, swelling of extremities, and joint pain was assessed at Baseline and at the end of the extension treatment period. The percentage of participants with improved or maintained (no change) acromegaly symptoms from Baseline at the end of the extension treatment period is reported.

Time frame: Baseline and the end of the extension treatment period (up to 13 months)

Percentage of Participants With ≥ 1, 2, or 3 Acromegaly Symptoms at Baseline and at the End of the Extension Treatment Period

Reported is the percentage of participants who had ≥ 1, 2, or 3 of the 5 symptoms of acromegaly (headaches, perspiration, asthenia, swelling of extremities, or joint pain) of any severity (mild, moderate, or severe). This was a post hoc analysis.

Time frame: Baseline and the end of the extension treatment period (up to 13 months)